S. Korea to introduce Merck's COVID-19 pill for 100,000 patients

2022-03-21 06:30:09

(Molnupiravir, Merck's COVID-19 pill)

Asian Tech Press (Mar. 21) -- South Korea will introduce Merck's COVID-19 pill molnupiravir, which is under the brand name Lagevrio, for 100,000 patients this week.

Interior Minister Jeon Hae-cheol said Monday that the planned introduction of molnupiravir comes amid rising demand for such oral COVID-19 medicine, according to Yonhap News Agency.

The Korean government is carefully considering authorizing molnupiravir for high-risk patients with mild to moderate symptoms who cannot take Pfizer Inc.'s Paxlovid or Gilead Sciences Inc.'s Remdesivir for COVID-19 treatment

"On top of the planned introduction of Paxlovid for 95,000 patients in April, the government is seeking early procurement of additional oral COVID-19 drugs," Jeon noted.

COVID-19 pill Merck molnupiravir South Korea

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Southwest Airlines CEO: Although Boeing still has a lot of work to do, they seem to be moving in a good direction and we are more optimistic.
                            2025-01-31

                                    White House Press Secretary Levitt: Details about the Nvidia meeting are still unclear.
                            2025-02-01

                                    Apple (AAPL.O) said the Apple Pay outage has been resolved.
                            2025-01-29

                                    Jefferies: Raised Meta Platforms (META.O) price target from $715 to $810.
                            2025-01-30

                                    Sam Altman, founder and CEO of OpenAI: OpenAI will develop specialized hardware for AI.
                            2025-02-03